1. Home
  2. RPRX vs STN Comparison

RPRX vs STN Comparison

Compare RPRX & STN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • STN
  • Stock Information
  • Founded
  • RPRX 1996
  • STN 1954
  • Country
  • RPRX United States
  • STN Canada
  • Employees
  • RPRX N/A
  • STN N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • STN Military/Government/Technical
  • Sector
  • RPRX Health Care
  • STN Consumer Discretionary
  • Exchange
  • RPRX Nasdaq
  • STN Nasdaq
  • Market Cap
  • RPRX 13.9B
  • STN 12.0B
  • IPO Year
  • RPRX 2020
  • STN N/A
  • Fundamental
  • Price
  • RPRX $36.03
  • STN $109.03
  • Analyst Decision
  • RPRX Strong Buy
  • STN
  • Analyst Count
  • RPRX 3
  • STN 0
  • Target Price
  • RPRX $47.33
  • STN N/A
  • AVG Volume (30 Days)
  • RPRX 4.3M
  • STN 167.6K
  • Earning Date
  • RPRX 08-07-2025
  • STN 08-06-2025
  • Dividend Yield
  • RPRX 2.44%
  • STN 0.42%
  • EPS Growth
  • RPRX 37.60
  • STN 14.85
  • EPS
  • RPRX 2.45
  • STN 2.34
  • Revenue
  • RPRX $2,263,845,000.00
  • STN $4,208,787,002.00
  • Revenue This Year
  • RPRX $29.35
  • STN $11.87
  • Revenue Next Year
  • RPRX $7.58
  • STN $7.82
  • P/E Ratio
  • RPRX $14.72
  • STN $46.90
  • Revenue Growth
  • RPRX 1.13
  • STN 16.16
  • 52 Week Low
  • RPRX $24.05
  • STN $73.18
  • 52 Week High
  • RPRX $36.32
  • STN $109.67
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 64.81
  • STN 68.25
  • Support Level
  • RPRX $35.01
  • STN $106.41
  • Resistance Level
  • RPRX $36.14
  • STN $107.68
  • Average True Range (ATR)
  • RPRX 0.70
  • STN 1.41
  • MACD
  • RPRX 0.10
  • STN -0.44
  • Stochastic Oscillator
  • RPRX 90.07
  • STN 98.09

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About STN Stantec Inc

Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.

Share on Social Networks: